Develops drugs for cancer with specific genetic alterations.
Jun 2026Revenue $53.8M/yrExpenses $190M/yr
No trendCash runway ≈ 7.0 years from Jun 2026
Figures by year
When will Tango Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $53.8M and expenses $190M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $62.4M | $174M | −$111M |
| Dec 2024 | $42.1M | $188M | −$146M |
| Dec 2023 | $36.5M | $151M | −$114M |
| Dec 2022 | $24.9M | $136M | −$111M |
| Dec 2021 | $37.0M | $95.2M | −$58.2M |
| Dec 2020 | $7.66M | $59.9M | −$52.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.